Falcinelli, S. D. et al. Longitudinal dynamics of intact HIV proviral DNA and outgrowth virus frequencies in a cohort of individuals receiving antiretroviral therapy. J. Infect. Dis. 224, 92–100 (2021).
Bouchat, S. & Van Lint, C. [Viral latency of HIV-1]. Virologie (Montrouge). 23, 195–210 (2019).
Ho, Y. C. et al. Replication-Competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013).
Armani-Tourret, M. et al. Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. Nat. Rev. Microbiol. 22, 328–344 (2024).
Jiang, C. et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585, 261–267 (2020).
Sáez-Cirión, A. et al. Post-Treatment HIV-1 controllers with a Long-Term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 9, e1003211 (2013).
Mzingwane, M. L. & Tiemessen, C. T. Mechanisms of HIV persistence in HIV reservoirs. Rev. Med. Virol. 27 (2017).
Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 1, e13–e21 (2014).
Søgaard, O. S. et al. The depsipeptide Romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).
Archin, N. M. et al. Administration of Vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
Dybul, M. et al. Pilot study of the effects of intermittent Interleukin-2 on human immunodeficiency virus (HIV)–Specific immune responses in patients treated during recently acquired HIV infection. J. INFECT. DIS. 185, 61–68 (2002).
Stellbrink, H. J. et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16, 1479–1487 (2002).
Tsai, P. et al. In vivo analysis of the effect of Panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Retrovirology 13, 36 (2016).
Gutiérrez, C. et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS 30, 1385–1392 (2016).
Banga, R. et al. PD-1 + and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754–761 (2016).
Evans, V. A. et al. Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS 32, 1491–1497 (2018).
Rasmussen, T. A. et al. Impact of Anti–PD-1 and Anti–CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS malignancy consortium 095 study. Clin. Infect. Dis. 73, e1973–e1981 (2021).
Guihot, A. et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann. Oncol. 29, 517–518 (2018).
Gay, C. L. et al. Safety and immune responses following Anti-PD-1 monoclonal antibody infusions in healthy persons with human immunodeficiency virus on antiretroviral therapy. Open. Forum Infect. Dis. 11, ofad694 (2024).
Gay, C. L. et al. Clinical trial of the Anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J. Infect. Dis. 215, 1725–1733 (2017).
Baron, M. et al. Impact of anti PD-1 immunotherapy on HIV reservoir and anti-Viral immune responses in people living with HIV and cancer. Cells 11, 1015 (2022).
Lau, J. S. Y. et al. The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. AIDS 35, 1631–1636 (2021).
Coffin, J. M. et al. Clones of infected cells arise early in HIV-infected individuals. JCI Insight. 4, e128432 (2019).
Cole, B. et al. In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. Nat. Commun. 12, 3727 (2021).
Patro, S. C. et al. Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. Proc. Natl. Acad. Sci. U S A. 116, 25891–25899 (2019).
Einkauf, K. B. et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J. Clin. Invest. 129, 988–998 (2019).
Assoumou, L. et al. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the National prospective real-world oncovihac ANRS CO24 cohort study. J. Immunother Cancer. 12, e009728 (2024).
Joseph, K. W. et al. Deep sequencing analysis of individual HIV-1 proviruses reveals frequent asymmetric long terminal repeats. J. Virol. 96, e00122–e00122 (2022).
Véronique, A. et al. LTR real-time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J. Med. Virol. 81, 217–223 (2009).
White, J. A. et al. Measuring the latent reservoir for HIV-1: quantification bias in near full-length genome sequencing methods. PLoS Pathog. 18, e1010845 (2022).
Wagner, T. A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570–573 (2014).
Shao, W. et al. Retrovirus integration database (RID): a public database for retroviral insertion sites into host genomes. Retrovirology 13, 47 (2016).
Zhao, M., Kim, P., Mitra, R., Zhao, J. & Zhao, Z. TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res. 44, D1023–D1031 (2016).
Sondka, Z. et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 52, D1210–D1217 (2024).
Sadelain, M., Papapetrou, E. P. & Bushman, F. D. Safe harbours for the integration of new DNA in the human genome. Nat. Rev. Cancer. 12, 51–58 (2012).
De Tribolet-Hardy, J. et al. Genetic features and genomic targets of human KRAB-zinc finger proteins. Genome Res. 33, 1409–1423 (2023).
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. EdgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
Mohammadi, A. et al. Viral and host mediators of non-suppressible HIV-1 viremia. Nat. Med. 29, 3212–3223 (2023).
Nobles, C. L. et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J. Clin. Invest. 130, 673–685 (2019).
Huang, A. S. et al. Integration features of intact latent HIV-1 in CD4 + T cell clones contribute to viral persistence. J. Exp. Med. 218, e20211427 (2021).
Lian, X. et al. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell. Host Microbe. 31, 83–96e5 (2023).
Robson, M. I. et al. Constrained release of lamina-associated enhancers and genes from the nuclear envelope during T-cell activation facilitates their association in chromosome compartments. Genome Res. 27, 1126–1138 (2017).
Komaki, S. et al. iMETHYL: an integrative database of human DNA methylation, gene expression, and genomic variation. Hum. Genome Var. 5, 18008 (2018).
Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).
Einkauf, K. B. et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell 185, 266–282e15 (2022).
Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094–3100 (2018).
Li, H. et al. The sequence alignment/map format and samtools. Bioinformatics 25, 2078–2079 (2009).
Shao, W. et al. HIV proviral sequence database: A new public database for near Full-Length HIV proviral sequences and their Meta-Analyses. AIDS Res. Hum. Retroviruses. 36, 1–3 (2020).
Rose, P. P. & Korber, B. T. Detecting hypermutations in viral sequences with an emphasis on G → A hypermutation. Bioinformatics 16, 400–401 (2000).
Ferreira, F. A. et al. HIV-1 proviral landscape characterization varies by pipeline analysis. J. Int. AIDS Soc. 24, e25725 (2021).
Tamura, K., Stecher, G. & Kumar, S. MEGA11: molecular evolutionary genetics analysis version 11. Mol. Biol. Evol. 38, 3022–3027 (2021).
Kuraku, S., Zmasek, C. M., Nishimura, O. & Katoh, K. aLeaves facilitates on-demand exploration of metazoan gene family trees on MAFFT sequence alignment server with enhanced interactivity. Nucleic Acids Res. 41, W22–W28 (2013).
Criscuolo, A. & Gribaldo, S. BMGE (Block mapping and gathering with Entropy): a new software for selection of phylogenetic informative regions from multiple sequence alignments. BMC Evol. Biol. 10, 210 (2010).
Nguyen, L. T., Schmidt, H. A., Von Haeseler, A. & Minh, B. Q. IQ-TREE: A fast and effective stochastic algorithm for estimating Maximum-Likelihood phylogenies. Mol. Biol. Evol. 32, 268–274 (2015).
Letunic, I. & Bork Interactive tree of life (iTOL) v6: recent updates to the phylogenetic tree display and annotation tool. Nucleic Acids Res. gkae268 https://doi.org/10.1093/nar/gkae268 (2024).
Gaube, G. et al. Characterization of HIV-1 diversity in various compartments at the time of primary infection by ultradeep sequencing. Sci. Rep. 10, 2409 (2020).
Uldrick, T. S. et al. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Sci. Transl Med. 14, eabl3836 (2022).
Coffin, J. M. et al. Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy. PLoS Pathog. 17, e1009141 (2021).
Maldarelli, F. et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).
Cesana, D. et al. HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. Nat. Commun. 8, 498 (2017).
Marini, B. et al. Nuclear architecture dictates HIV-1 integration site selection. Nature 521, 227–231 (2015).
Chen, H. C., Martinez, J. P., Zorita, E., Meyerhans, A. & Filion, G. J. Position effects influence HIV latency reversal. Nat. Struct. Mol. Biol. 24, 47–54 (2017).
Cano-Gamez, E. et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4 + T cells to cytokines. Nat. Commun. 11, 1801 (2020).
McMyn, N. F. et al. The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. J. Clin. Invest. 133, e171554 (2023).
Sguanci, L., Bagnoli, F. & Liò, P. Modeling HIV quasispecies evolutionary dynamics. BMC Evol. Biol. 7, S5 (2007).
Charpentier, C., Nora, T., Tenaillon, O., Clavel, F. & Hance, A. J. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J. Virol. 80, 2472–2482 (2006).
Imamichi, H. et al. Defective HIV-1 proviruses produce viral proteins. Proc. Natl. Acad. Sci. U.S.A. 117, 3704–3710 (2020).
Pollack, R. A. et al. Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape. Cell. Host Microbe. 21, 494–506e4 (2017).
Wertheim, J. O. et al. Social and genetic networks of HIV-1 transmission in new York City. PLoS Pathog. 13, e1006000 (2017).
Guo, S. et al. HIV infected CD4 + T cell clones are more stable than uninfected clones during long-term antiretroviral therapy. PLoS Pathog. 18, e1010726 (2022).
Chiu, C. Y. et al. Combination immune checkpoint Blockade enhances IL-2 and CD107a production from HIV-Specific T cells ex vivo in people living with HIV on antiretroviral therapy. J. Immunol. 208, 54–62 (2022).
Sanjuán, R., Nebot, M. R., Peris, J. B. & Alcamí, J. Immune activation promotes evolutionary conservation of T-Cell epitopes in HIV-1. PLoS Biol. 11, e1001523 (2013).
Allen, T. M. et al. Selective escape from CD8 + T-Cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79, 13239–13249 (2005).
Benito, J. M., Restrepo, C., García-Foncillas, J. & Rallón, N. Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV. Front. Immunol. 14, 1270881 (2023).
Vibholm, L. K. et al. Characterization of intact proviruses in blood and lymph node from HIV-Infected individuals undergoing analytical treatment interruption. J. Virol. 93, e01920–e01918 (2019).
